1. Introduction {#sec1}
===============

Metabolic syndrome (MS) is a complex disorder characterized by the clustering of several metabolic diseases such as abdominal obesity, insulin resistance (IR), elevated plasma triglycerides level (TG), low high density lipoprotein cholesterol (cHDL), high blood pressure, and altered glucose homeostasis \[[@B1]\]. Environmental factors such as low physical activity and inappropriate dietary habits are strong determinants of the MS. In addition, genetic factors also contribute to the individual susceptibility to MS \[[@B2]\].

All components of the MS have individually been associated with the incidence and progression of chronic kidney diseases (CKDs). The mechanisms and impacts of hypertensive and diabetic injuries, the two major etiologies of CKD in the world, have been well studied and described \[[@B3]--[@B5]\]. Several observational studies found that individuals with the MS are at increased risk for presenting renal manifestations, namely, microalbuminuria and decreased glomerular filtration rate (GFR). In fact, epidemiological studies have linked MS with an increased risk for microalbuminuria, an early marker of glomerular injury and endothelial dysfunction \[[@B6]--[@B8]\].

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors. They are ligand-dependent intracellular proteins that stimulate transcription of specific genes by binding to specific DNA sequences \[[@B9]\]. There are three PPAR subtypes, products of the distinct genes commonly designated as PPAR*α*, PPAR*γ*, and PPAR *β*/*δ* and expressed in various tissues \[[@B10]--[@B13]\]. In humans, renal PPAR*α* and PPAR*γ* isotypes are abundantly expressed \[[@B14], [@B15]\].

In this regard, two common polymorphisms affecting the amino acid sequence of the PPAR*α* and PPAR*γ*2 gene are relevant candidates, the Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2. We, therefore, assessed the potential relationships of these polymorphisms variants for their individual effect as well as their interactive impact on MS and renal injuries.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

522 subjects undergoing routine control were investigated for biochemical, anthropometric, and clinical examination at the occupational medicine of the University Hospital of Monastir, Tunisia. All the subjects enrolled in this study were coming from central Tunisia and there were no consanguinity relationships among them. Participants gave their written informed consent prior to their participation. The study was approved by the ethical committee of the hospital.

2.2. Diagnostic Criteria for Metabolic Syndrome {#sec2.2}
-----------------------------------------------

The diagnosis of MS was based on the IDF and AHA/NHLBI definition, which requires the presence of at least three of the following criteria: the central (abdominal) obesity (defined as waist circumference (WC) ≥94 cm in men and ≥80 cm in women), the raised TG ≥1.70 mmol/L (drug treatment for elevated triglycerides is an alternate indicator), the reduced cHDL \<1.04 mmol/L in men and \<1.29 mmol/L in women (or specific treatment for this lipid abnormality), the elevated systolic blood pressure (SBP) ≥130 mmHg and/or diastolic blood pressure (DBP) ≥85 mmHg (antihypertensive drug treatment in a patient with a history of hypertension was an alternate indicator), and the elevated FPG ≥5.56 mmol/L or previously diagnosed type 2 diabetes \[[@B16]\].

2.3. Anthropometric Measurements {#sec2.3}
--------------------------------

Height and weight were measured according to a standardized protocol in the study population, with subjects wearing light clothing and no shoes. Body mass index (BMI) was calculated by dividing weight in kilograms by height in square meters (kg/m^2^). The waist circumference was measured in the horizontal plane at the midpoint between the lowest rib and the iliac crest. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured to the nearest 5 mmHg with a mercury sphygmomanometer, with subjects in a supine position and having relaxed for 5 minutes.

2.4. Biochemical Analysis {#sec2.4}
-------------------------

The blood samples of the study population were collected in the morning after a 12-hour fasting period, heparinazed serum was immediately obtained by blood centrifugation at 4°C at 3000 rpm for 15 min. All analyses were carried out in biochemistry and toxicology laboratory of the Hospital using a Cobas 6000TM analyzer (Roche Diagnostics Mannheim, Germany). Serum total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (cHDL), low density lipoprotein cholesterol (cLDL), and Uric acid (UA) serum levels and fasting plasma glucose (FPG) were determined by using enzymatic techniques. Fasting plasma insulin (FPI) was measured by electrochemiluminescence immuno assay (ECLIA), and serum creatinine concentration was determined by the kinetic Jaffe method.

The computer model HOMA 2 was used to determine *β*-cell function (HOMA-*β*%), insulin sensitivity (HOMA-S%), and insulin resistance (HOMA-IR) from paired fasting glucose (mmol/L) and insulin (mIU/L) concentrations \[[@B17]\].

Renal function was assessed by estimating the GFR, with the Cockcroft and Gault formula: $$\begin{matrix}
{\text{GFR}\,\left( {\text{mL}/{\min}} \right) = \frac{\left\lbrack {140 - \text{age}\,\left( \text{years} \right)} \right\rbrack\, \times \text{BM}\,\left( \text{kg} \right)}{0.814 \times \text{creatinine}\,\left( {{\mu\text{mol}}/\text{L}} \right)}.} \\
\end{matrix}$$ In female subjects, the result was multiplied by 0.85 \[[@B18]\].

2.5. Genetic Analysis {#sec2.5}
---------------------

Genotyping was carried out on genomic DNA extracted from subjects\' blood samples by salt fractionation. The primers used for polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) from the PPAR *α* Leu 162 Val SNP were 5′-GACTCAAGCTGGTGTATGACAAGT-3′ as the forward primer and the reverse-mismatch primer 5′CGTTGTGTGACATCCCGACAGAA[T]{.ul}-3′ with the mismatch nucleotide in the reverse primer underlined. A mixture of Taq polymerase 10X buffer 2.5 *μ*L, 0.2 *μ*L Taq DNA polymerase, 2 *μ*L dNTP, 10 pmol of each primer, and 6 *μ*L of template DNA was used at a total volume of 25 *μ*L, and the mixture was amplified in PCR equipment (TECHNE TC-312). The reaction was carried out using 30 cycles of predenaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and elongation at 72°C for 5 min. Electrophoresis was conducted in 1% agarose gel to confirm the 117 bp PCR product, and the restriction was performed by using 8 U of a Hinf I enzyme at 37°C overnight. The restriction site was confirmed at 3% agarose gel. The Leu/Leu homozygote produced 1 fragment at 117 bp, the Leu/Val heterozygote produced 3 fragments at 117, 93, and 24 bp, and the Val/Val homozygote produced 2 fragments at 93 and 24 bp. The primers used for PCR-RFLP from the PPAR*γ*2 Pro 12 Ala SNP were 5′-CAAGCCCAGGTCCTTTCTGTG-3′ as the forward primer and 5′-AGTGAAGGAATCGCTTTCCG-3′ as the reverse primer. A mixture of Taq polymerase 10X buffer 2.5 *μ*L, 0.2 *μ*L Taq DNA polymerase, 2 *μ*L dNTP, 10 pmol of each primer, and 6 *μ*L of template DNA was used at a total volume of 25 *μ*L, and the mixture was amplified in PCR equipment (TECHNE TC-312). The reaction was carried out using 30 cycles of predenaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 5 min. Electrophoresis was conducted in 1% agarose gel to confirm the 237 bp PCR product, and the restriction was performed by using 8 U of a HpaII enzyme at 37°C overnight. The restriction site was confirmed at 3% agarose gel. The Pro/Pro homozygote produced 2 fragments at 217 and 20 bp, the Pro/Ala heterozygote produced 3 fragments at 237, 217, and 20 bp, and the Ala/Ala homozygote produced 1 fragment at 237 bp, which did not splice when the HpaII restriction enzyme was used.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Data were analyzed by SPSS 17.0 for Windows. Continuous results that satisfied a normal distribution are expressed as mean ± standard deviation (SD). Those results that provided abnormal distribution data are expressed as median and quartile and frequencies for qualitative variables. Comparisons among groups were assessed using the independent-sample *t*-test for quantitative variables and Pearson\'s chi-square test for qualitative variables. The one-way analysis of variance (ANOVA) method was used to compare differences between genotype groups. Pearson\'s chi-square test (*χ* ^2^) was used to compare the genotype prevalence between different groups. The Hardy-Weinberg equilibrium was performed using the *χ* ^2^ test. A two-sided *P* \< 0.05 was considered as statistically significant.

3. Results {#sec3}
==========

Among the 522 subjects who were enrolled, 258 presented metabolic syndrome (SM^+^) and 264 were without (MS^−^). [Table 1](#tab1){ref-type="table"} shows that SM^+^ subjects have higher BMI, WC, SBP, DBP, TG, cLDL, TC, FPG, and FPI and reduced cHDL compared to subjects MS^−^. We also noted elevated IR and reduced HOMA *β* and HOMA S and higher creatinine, urea, and UA plasma level and reduced GFR in SM^+^ group.

The Pro/Pro genotype was present in 70.69% (369 subjects); Pro/Ala genotype in 27.59% (144 subjects) and Ala/Ala genotype was present in 1.72% (9 subjects) of 522 subjects. Allele frequencies were 0.845 for Pro allele and 0.155 for Ala allele. Allele frequency of the two genotypes satisfied the Hardy-Weinberg equilibrium. The Leu/Leu genotype was present in 84.48% (441 subjects), Leu/Val genotype in 14.17% (74 subjects), and Val/Val genotype in 1.35% (7 subjects) of 522 subjects. Allele frequencies were 0.916 for Leu allele and 0.084 for Val allele. Allele frequency of the two genotypes satisfied the Hardy-Weinberg equilibrium. The allelic frequency of Ala allele was significantly (*P* = 0.005) lower in MS^+^ group (0.124%) than in MS^−^ group (0.186). Also, the frequency of Val allele was significantly (*P* = 0.006) lower in MS^+^ group (0.061) than in MS^−^ group (0.108). Subjects with the Ala allele had a decreased risk for MS (odds ratio (OR) = 0.621, 95% CI (0.442--0.874)). The Val allele decreases the risk of MS (OR = 0.528, 95% CI (0.335--0.833)) ([Table 2](#tab2){ref-type="table"}).

The independent effects of each polymorphism on anthropometric and biochemical characteristics-related variables are presented in [Table 3](#tab3){ref-type="table"}. There were no differences among the genotypes in terms of age, BMI, blood pressure, TG, TC, cHDL, and cLDL either in X/Ala (Pro/Ala and Ala/Ala) PPAR*γ*2 or X/Val (Leu/Val and Val/Val) PPAR*α*. Subjects with Pro/Pro had a significantly higher FPG, FPI, and HOMA-IR. In parallel, creatinine, urea, and uric acid serum levels were found to be elevated in these Pro/Pro subjects. In addition, Pro/Pro subjects also display reduced HOMA-*β* and HOMA-S together with decreased GFR compared to X/Ala (Pro/Ala and Ala/Ala) subjects. Furthermore, subjects with Leu/Leu have only a significantly reduced HOMA-*β* and elevated creatinine, urea, and uric acid serum levels and a decreased GFR compared to X/Val (Leu/Val and Val/Val) subjects.

To check if the effects of the SNPs are associated with MS, subjects were divided into people displaying metabolic syndrome (SM^+^) or not (MS^−^) (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}). For Pro12Ala PPAR*γ*2 gene in the SM^+^ group, Ala allele carriers had higher HOMA-*β*, HOMA-S and GFR, and decreased FPG, FPI, HOMA-IR, creatinine, and urea serum levels compared to non-Ala allele carriers. For Leu162Val PPAR*α* gene, both groups did not show any significant difference on the measures.

To check if the effects of the SNPs are associated with age, we divided the subjects into two groups. The first group had subjects who were younger than 60 years old, and the second group had subjects that were 60 years old and more; here we compared the parameters related to MS between these two groups (Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"}). For Pro12Ala PPAR*γ*2 gene, in the group aged \<60 years old, Ala allele carriers had higher HOMA-*β* and HOMA-S and decreased FPG, FPI, HOMA-IR, creatinine, and urea serum levels than non-Ala allele carriers. For Pro12Ala PPAR*γ*2 gene, in the group aged ≥60 years old, Ala allele carriers had higher HOMA-S and GFR and decreased FPI and HOMA-IR than non-Ala allele carriers. For Leu162Val PPAR*α* gene, both groups showed significantly higher HOMA-*β* and reduced FPG levels in Val-carriers than Pro-carriers.

To check if the effects of the SNPs are associated with BMI, we divided the subjects into three groups, a lean group (BMI \< 25 kg/m^2^), an overweight group (BMI ≥ 25 kg/m^2^ and BMI ≤ 30 kg/m^2^), and obese group (BMI \> 30 kg/m^2^). We compared the genotype and allele frequency among the three groups by using Pearson\'s chi-square test (*χ* ^2^). There was no difference among the three groups in terms of both polymorphisms (*P* = 0.063, 0.902). Further analysis by gender was conducted and same result was achieved by both males and females. There was no difference found in terms of Leu162Val and Pro 12 Ala PPAR*γ*2 in genotype of both polymorphisms (*P* = 0.224, 0.889).

In order to evaluate the interaction between Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms, we divided the subjects into four groups according to the combination of the 2 genotypes from each SNP, that is, Leu/Leu PPAR*α* with Pro/Pro PPAR*γ*2 genotype (*n* = 329), Leu/Leu PPAR*α* with an Ala allele (*n* = 112), Leu/Val PPAR*α* with Pro/Pro PPAR*γ*2 (*n* = 40), and Leu/Val PPAR*α* with an Ala allele (*n* = 41), and compared the study parameters among the groups. There were no differences in the anthropometric measurements and lipid profile variables among the different combination groups of the polymorphisms. The Leu/Val genotype carries with an Ala allele group had significantly reduced FPG, FBI, HOMA-IR, urea, and UA levels and elevated HOMA-S, HOMA-*β*, and GFR compared to the different combination groups ([Table 8](#tab8){ref-type="table"}).

4. Discussion {#sec4}
=============

MS is a complex disorder resulting from the interaction between genetic and environmental factors. A major part of our study has focused on the genetics of PPAR*α* and PPAR*γ*2 polymorphisms. Understanding the genetics of these polymorphisms is not only important because it is associated with the MS, but also it has been recently recognized to be related to renal function \[[@B19]--[@B22]\]. The present study investigated the independent effect of Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms as well as their impact on glucose, insulin, HOMA index, urea, UA, and GFR.

We showed that carriers of the PPAR*α* Val162 allele had lower urea, UA, and raised GFR compared to those homozygous for the Leu162 allele. Also, subjects carrying the PPAR*γ*2 Ala allele had the same results. In addition, they had reduced FPG, FPI, and HOMA-IR and elevated HOMA-*β* and HOMA-S. The Leu/Val genotype carriers with an Ala allele group had lower FPG, PPI, HOMA-IR, urea, and UA levels and higher HOMA-*β*, HOMA-S, and GFR than other different genotype combinations. Thus, the effect of one allele in one gene seems to depend upon the presence of another allele in a second gene.

The Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms have opposite effects on the transcriptional activity of their respective receptors. Indeed, the Ala12 allele results in a less active form of PPAR*γ*2, while the Val162 allele results in a more active form of PPAR*α* \[[@B23]--[@B25]\]. However, the observation that the PPAR*γ*2 Ala12 allele mediates its lowering effect only on a PPAR*α* genetic background complicates the explanation. It demonstrated that the PPAR*γ*2 Ala12 allele was associated with greater insulin sensitivity \[[@B25]\]. Similarly, the Ala12 allele in PPAR*γ*2 attenuates the effect of the PPAR*α* Val162 allele on glucose and insulin homeostasis \[[@B26]\]. Genetic variation in PPAR*γ* coactivator-1, which also coactivates PPAR*α*, influences the insulin secretory response \[[@B27]\].

Many studies found a significant association between MS and CKD and consistently demonstrated an increased risk parallel to the number of MS traits \[[@B28]--[@B30]\]. The association between MS and renal damage is, in part, explained by hypertension and impaired glucose metabolism. However, the underlying mechanisms include an increasing body mass, insulin resistance, inflammation, renal endothelial dysfunction, oxidative stress, and altered renal haemodynamics, activation of the renin-angiotensin-aldosterone system and sympathetic nervous system, and dietary factors \[[@B31]\].

Urine analysis and blood biochemistry have been of great help in the assessment of renal function. Uric acid is an end product of purine (a component of nucleic acids and nucleoproteins) metabolism; urea is an end product of protein metabolism and the creatinine is derived from the creatine and is a waste product. The major cause of increased levels of plasma creatinine, urea, and uric acid is the poor clearance of these substances by the kidneys rather than excessive production. Insulin may induce renal fibrosis by stimulating mesangial cells and proximal tubule cells to produce tumor growth factor *β* (TGF-*β*) \[[@B32], [@B33]\].

Insulin stimulates the production of insulin-like growth factory 1 (IGF-1) by vascular smooth muscle cells and other cell types, which have been implicated in the development of diabetic kidney disease \[[@B34]\]. IGF-1 increases the activity of connective tissue growth factor, a cytokine that has profibrogenic actions on renal tubular cells and interstitial fibroblasts. In addition, IGF-1 decreases the activity of matrix metalloproteinase-2, an enzyme responsible for extracellular matrix degradation, thereby promoting extracellular matrix expansion and renal fibrosis \[[@B35], [@B36]\]. Additionally, IR promotes sodium and UA reabsorption resulting in salt-sensitive hypertension and hyperuricemia \[[@B37]\].

Insulin resistance and the release of inflammatory cytokines induce mesangial expansion, basement membrane thickening, podocytopathy, and loss of slit pore diaphragm integrity leading to the so-called obesity-related glomerulopathy \[[@B38], [@B39]\]. In accordance with the results of other studies, expression of PPAR*α* in glomerular mesangial cells has also been reported. Thus, it is likely that PPAR*α* activation in mesangial cells could block TGF-*β* signalling pathway by attenuating glomerular matrix proliferation. Therefore, it is likely that PPAR*α* activation may facilitate albumin reabsorption and degradation in the nephron segment \[[@B40], [@B42]\]. Bossé et al. observed a deleterious effect of the PPAR*α* Val162 allele on glucose and insulin levels during a glucose challenge but suggested that Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms interact with each other to modulate some features of glucose and insulin homeostasis \[[@B43]\]. Moreover, it was found that the Ala-allele is associated with enhanced decline in GFR and predicts end-stage renal disease (ESRD) and all-cause mortality in patients with nephropathy \[[@B44]\].

Taken together, these observations may partly explain the synergetic effect of Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms on MS and renal injuries.

5. Conclusion {#sec5}
=============

We suggest that Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms can interact with each other to modulate glucose and insulin homeostasis and expand their association with the overall renal function. However, a replication of this study is required before a firm conclusion can be reached.

###### 

Anthropometric and biochemical characteristics of study population.

  ----------------------------------------------------------------------------
  Variables             MS^−^ (*n* = 264)      MS^+^ (*n* = 258)     *P*
  --------------------- ---------------------- --------------------- ---------
  Age (years)           41.0 (29.0--51.7)      38.0 (29.0--54.0)     0.695

  Gender M/F (%)        137/127 (51.9/48.1)    128/130 (49.6/50.4)   0.602

  Diabetes (*n* (%))    31 (11.7)              71 (27.9)             \<0.001

  Hypertension\         36 (13.6)              101 (39.7)            \<0.001
  (*n* (%))                                                          

  SBP (mmHg)            120 (115--125)         140 (130--150)        \<0.001

  DBP (mmHg)            80 (75--80)            85 (80--90)           \<0.001

  BMI (kg/m^2^)         24.5 (23.7--25.9)      27.7 (26.4--29.4)     \<0.001

  Men WC (cm)           93 (89--95)            98 (96--101)          \<0.001

  Women WC (cm)         79 (77--86)            93 (90--98)           \<0.001

  TG (mmol/L)           1.07 ± 0.44            1.91 ± 0.71           \<0.001

  TC (mmol/L)           4.51 (4.12--4.99)      5.15 (4.24--5.78)     \<0.001

  cLDL (mmol/L)         2.92 (2.52--3.31)      3.36 (2.76--3.95)     \<0.001

  Men cHDL (mmol/L)     1.10 (1.02--1.16)      0.84 (0.74--0.92)     \<0.001

  Women cHDL (mmol/L)   1.45 (1.34--1.53)      1.10 (0.89--1.26)     \<0.001

  FPG (mmol/L)          4.94 ± 0.95            6.96 ± 1.78           \<0.001

  FPI (mIU/L)           7.12 (5.97--8.61)      12.73 (9.59--13.22)   \<0.001

  HOMA-*β*%             97 (88--109)           72 (52--94)           \<0.001

  HOMA-S%               110 (88--130)          56 (53--78)           \<0.001

  HOMA-IR               0.9 (0.8--1.1)         1.8 (1.3--1.9)        \<0.001

  Cr (*μ*mol/L)         87.5 ± 31              111.4 ± 46.4          \<0.001

  Urea (mmol/L)         4.46 ± 2.63            7.72 ± 4.82           \<0.001

  UA (*μ*mol/L)         267.5 (213.5--307.7)   358 (285--4.28)       \<0.001

  GFR (mL/min)          92.9 (78.8--107.4)     85.6 (61.9--106.3)    0.004
  ----------------------------------------------------------------------------

MS^−^: without metabolic syndrome; MS^+^: with metabolic syndrome, SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 genotype and allele distribution.

                       Total (522)     MS^−^ (264)   MS^+^ (258)   *P*     OR (95% CI)
  -------------------- --------------- ------------- ------------- ------- ----------------------
  Pro12 Ala PPAR*γ*2                                                       
                                                                           
  Allele                                                                   
  Pro (*n* (%))        882 (84.5)^a^   430 (81.4)    452 (87.6)    0.006   1.610 (1.144--2.265)
  Ala (*n* (%))        162 (15.5)      98 (18.6)     64 (12.4)     0.006   0.621 (0.442--0.874)
  Genotype                                                                 
  Pro/Pro (*n* (%))    369 (70.69)     174 (65.91)   195 (75.58)   0.015   1.601 (1.093--2.344)
  Pro/Ala (*n* (%))    144 (27.59)     82 (31.06)    62 (24.03)    0.046   0.675 (0.458--0.995)
  Ala/Ala (*n* (%))    9 (1.72)        8 (3.03)      1(0.39)       0.013   0.112 (0.014--0.901)
                                                                           
  Leu162Val PPAR*α*                                                        
                                                                           
  Allele                                                                   
  Leu (*n* (%))        956 (91.6)      471 (89.2)    485 (93.9)    0.005   1.893 (1.201--2.985)
  Val (*n* (%))        88 (8.4)        57 (10.8)     31 (6.1)      0.005   0.528 (0.335--0.833)
  Genotype                                                                 
  Leu/Leu (*n* (%))    441 (84.48)     213 (80.68)   228 (88.37)   0.015   1.820 (1.117--2.985)
  Leu/Val (*n* (%))    74 (14.17)      45 (17.05)    29 (11.24)    0.046   0.602 (0.364--0.995)
  Val/Val (*n* (%))    7 (1.35)        6 (2.27)      1 (0.39)      0.049   0.156 (0.019--1.304)

^a^Number (% of total); SM^−^: without metabolic syndrome; SM^+^: with metabolic syndrome; OR: odds ratio; CI: confidence interval.

###### 

Anthropometric, HOMA index, and biochemical characteristics of subjects with different groups of genotype of the Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms.

  -------------------------------------------------------------------------------------------------------------
  Parameters      Pro12Ala PPAR*γ*2   Leu162Val PPAR*α*                                               
  --------------- ------------------- ------------------- --------- ---------------- ---------------- ---------
  Age (years)     41 (29--53)         38 (28--49)         0.088     39 (29--53)      38 (29--48)      0.177

  SBP (mmHg)      125\                125\                0.102     125\             130\             0.854
                  (120--140)          (120--135)                    (120--140)       (120--135)       

  DBP (mmHg)      80 (80--85)         80 (80--85)         0.127     80 (80--85)      80 (80--85)      0.465

  BMI (kg/m^2^)   26.4\               25.6\               0.108     25.9\            26.6\            0.201
                  (24.4--28.3)        (24.1--27.9)                  (24.3--28.2)     (24.4--29.1)     

  WC (cm)         93.0\               93.0\               0.404     93.0\            94.0\            0.076
                  (85.0--98.0)        (81.5--97)                    (83.0--97.0)     (86.5--98.5)     

  TG (mmol/L)     1.51 ± 0.71         1.43 ± 0.76         0.186     1.50 ± 0.72      1.44 ± 0.72      0.497

  TC (mmol/L)     4.73\               4.71\               0.271     4.72\            4.71\            0.526
                  (4.19--5.49)        (4.11--5.27)                  (4.19--5.45)     (4.12--5.41)     

  cLDL (mmol/L)   3.09\               3.00\               0.513     3.07\            3.09\            0.410
                  (2.61--3.71)        (2.62--3.67)                  (2.62--3.73)     (2.57--3.63)     

  cHDL (mmol/L)   1.12\               1.09\               0.368     1.11\            1.12\            0.475
                  (0.88--1.27)        (0.90--1.34)                  (0.88--1.29)     (0.92--1.33)     

  FPG (mmol/L)    6.14 ± 1.77         5.45 ± 1.57         \<0.001   6.05 ± 1.79      5.36 ± 1.30      0.001

  FPI (mIU/L)     9.83\               7.85\               \<0.001   9.23\            8.91\            0.139
                  (7.12--12.88)       (6.16--11.22)                 (6.92--12.83)    (6.65--11.95)    

  HOMA-*β*%       86\                 95\                 \<0.001   88\              95\              \<0.001
                  (64--100)           (82--105)                     (67--99)         (80--119)        

  HOMA-S%         77\                 102\                \<0.001   80\              85\              0.043
                  (54--109)           (68--126)                     (55--112)        (62--118)        

  HOMA-IR         1.3 (0.9--1.8)      1.0 (0.8--1.5)      \<0.001   1.2 (0.9--1.8)   1.2 (0.9--1.6)   0.067

  Cr (*μ*mol/L)   102.1 ± 45.8        92.5 ± 25.2         0.016     99.6 ± 41.6      97.9 ± 38.2      0.749

  Urea (mmol/L)   6.45 ± 4.33         5.17 ± 2.34         0.001     6.29 ± 4.13      4.89 ± 1.83      0.003

  UA (*μ*mol/L)   307\                292\                0.036     306\             292\             0.042
                  (248--385)          (234--350)                    (247--382)       (233--341)       

  GFR (mL/min)    89.5\               93.8\               0.004     89.0\            102.6\           0.002
                  (72.7--105.1)       (71.6--111.3)                 (71.5--104.9)    (76.1--113.5)    
  -------------------------------------------------------------------------------------------------------------

P: Pro; A: Ala; L: Leu; V: Val; X/A: Pro/Ala and Ala/Ala; X/V: Leu/Val and Val/Val.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Comparison of anthropometric, HOMA index, and biochemical characteristics of subjects between different groups of Pro12Ala PPAR*γ*2 genotypes in two subdivided groups according to metabolic syndrome.

  -----------------------------------------------------------------------------------------------------
  Parameters      SM^−^            SM^+^                                                      
  --------------- ---------------- ---------------- ------- ---------------- ---------------- ---------
  Age (years)     42 (29--53)      38 (28--49)      0.455   39 (29--56)      37 (28--49)      0.103

  SBP (mmHg)      120 (115--125)   120 (115--125)   0.708   140 (130--150)   140 (130--145)   0.675

  DBP (mmHg)      80 (75--80)      80 (70--80)      0.277   85 (80--90)      85 (80--90)      0.965

  BMI (kg/m^2^)   24.5\            24.4\            0.228   27.7\            27.6\            0.940
                  (23.8--25.9)     (23.6--25.7)             (26.3--29.4)     (26.5--29.3)     

  WC (cm)         87 (79--93)      90 (79--93)      0.758   96 (92--99)      96 (93--99)      0.997

  TG (mmol/L)     1.07 ± 0.43      1.07 ± 0.43      0.942   1.91 ± 0.67      1.92 ± 0.84      0.964

  TC (mmol/L)     4.51\            4.62\            0.633   5.18\            4.81\            0.190
                  (4.15--4.85)     (4.02--5.17)             (4.27--5.78)     (4.19--5.59)     

  cLDL (mmol/L)   2.90\            2.98\            0.729   3.48\            3.24\            0.499
                  (2.54--3.29)     (2.40--3.53)             (2.76--4.10)     (2.85--3.85)     

  cHDL (mmol/L)   1.18\            1.19\            0.868   0.91\            0.92\            0.925
                  (1.11--1.43)     (1.04--1.46)             (0.79--1.17)     (0.77--1.14)     

  FPG (mmol/L)    4.94 ± 1.09      4.95 ± 0.87      0.946   7.21 ± 1.67      6.16 ± 1.86      \<0.001

  FPI (mIU/L)     7.13\            6.93\            0.277   12.83\           10.58\           \<0.001
                  (6.14--8.65)     (5.61--8.58)             (10.76--13.29)   (7.92--12.98)    

  HOMA-*β*%       96 (87--111)     97 (88--106)     0.698   68 (52--88)      86 (71--101)     \<0.001

  HOMA-S%         108 (87--128)    113 (89--140)    0.270   56 (53--66)      70 (55--103)     \<0.001

  HOMA-IR         0.9 (0.8--1.2)   0.9 (0.7--1.1)   0.282   1.8 (1.5--1.9)   1.4 (1.0--1.8)   \<0.001

  Cr (*μ*mol/L)   87.29 ± 36.16    87.87 ± 25.2     0.579   115.35 ± 49.51   99.30 ± 32.42    0.017

  Urea (mmol/L)   4.52 ± 3.05      4.35 ± 17.24     0.619   6.33 ± 2.78      8.16 ± 4.58      0.003

  UA (*μ*mol/L)   268\             266\             0.996   358\             348\             0.062
                  (210--313)       (215--306)               (285--437)       (278--396)       

  GFR (mL/min)    93.4\            91.5\            0.192   84.0\            98.8\            0.001
                  (82.3--106.4)    (70.5--109.1)            (58.8--104.5)    (78.8--113.8)    
  -----------------------------------------------------------------------------------------------------

P: Pro; A: Ala; X/A: Pro/Ala and Ala/Ala.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Comparison of anthropometric, HOMA index, and biochemical characteristics of subjects between different groups of Leu162Val PPAR*α* genotypes in two subdivided groups according to metabolic syndrome.

  ---------------------------------------------------------------------------------------------------
  Parameters      SM^−^            SM^+^                                                      
  --------------- ---------------- ---------------- ------- ---------------- ---------------- -------
  Age (years)     42 (29--52)      38 (32--49)      0.566   39 (29--56)      36 (29--45)      0.898

  SBP (mmHg)      120\             120\             0.073   140\             135\             0.300
                  (115--120)       (120--130)               (130--150)       (130--150)       

  DBP (mmHg)      80 (75--80)      80 (75--80)      0.260   85 (80--90)      85 (80--90)      0.090

  BMI (kg/m^2^)   24.5\            25.0\            0.172   27.7\            27.6\            0.400
                  (23.7--25.8)     (23.9--28.1)             (26.4--29.4)     (26.5--29.4)     

  WC (cm)         86\              93\              0.658   96\              96\              0.615
                  (79--93)         (84--97)                 (92--99)         (93--100)        

  TG (mmol/L)     1.06 ± 0.44      1.09 ± 0.42      0.691   1.90 ± 0.70      2.02 ± 0.77      0.382

  TC (mmol/L)     4.51\            4.53\            0.659   5.15\            5.12\            0.330
                  (4.14--4.93)     (3.90--5.06)             (4.22--5.78)     (4.23--5.78)     

  cLDL (mmol/L)   2.92\            2.97\            0.717   3.42\            3.30\            0.351
                  (2.52--3.31)     (2.31--3.40)             (2.76--4.03)     (2.83--3.85)     

  cHDL (mmol/L)   1.19\            1.16\            0.777   0.90\            0.95\            0.935
                  (1.10--1.46)     (1.04--1.39)             (0.79--1.14)     (0.82--1.28)     

  FPG (mmol/L)    4.94 ± 0.96      4.96 ± 0.88      0.846   7.08 ± 1.76      6.02 ± 1.60      0.002

  FPI (mIU/L)     7.06\            7.48\            0.626   12.77\           11.26\           0.879
                  (5.86--8.25)     (6.17--10.04)            (10.09--13.25)   (7.85--13.03)    

  HOMA-*β*%       97\              100\             0.283   69\              85\              0.219
                  (88--105)        (86--121)                (52--93)         (66--106)        

  HOMA-S%         111\             103\             0.602   56\              64\              0.564
                  (95--134)        (75--126)                (53--73)         (56--99)         

  HOMA-IR         0.9 (0.8--1.1)   1.0 (0.8--1.3)   0.761   1.8 (1.4--1.9)   1.6 (1.0--1.8)   0.457

  Cr (*μ*mol/L)   86.3 ± 32.6      92.3 ± 22.5      0.216   111.9 ± 45.2     107.6 ± 54.7     0.631

  Urea (mmol/L)   4.55 ± 2.87      4.12 ± 1.17      0.303   7.92 ± 4.46      6.02 ± 2.01      0.039

  UA (*μ*mol/L)   268\             250\             0.752   358\             348\             0.847
                  (206--313)       (223--302)               (285--433)       (288--398)       

  GFR (mL/min)    91.7\            99.1\            0.302   84.5\            108.8\           0.679
                  (79.4--105.8)    (71.6--109.4)            (60.4--104.7)    (82.1--124.5)    
  ---------------------------------------------------------------------------------------------------

L, Leu; V, Val; X/V: Leu/Val and Val/Val.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Comparison of anthropometric, HOMA index, and biochemical characteristics of subjects between different groups of Pro12Ala PPAR*γ*2 genotypes in two subdivided groups according to age.

  ------------------------------------------------------------------------------------------------------
  Parameters      Age \< 60 years   Age ≥ 60 years                                               
  --------------- ----------------- ---------------- --------- ---------------- ---------------- -------
  Age (years)     36 (29--46)       35 (28--41)      0.094     62 (59--66)      64 (59--69)      0.287

  SBP (mmHg)      125\              125\             0.110     130\             130\             0.845
                  (120--140)        (120--130)                 (120--140)       (120--140)       

  DBP (mmHg)      80 (80--85)       80 (80--80)      0.065     80 (80--85)      80 (75--90)      0.709

  BMI (kg/m^2^)   26.0\             25.4\            0.276     26.9\            25.9\            0.237
                  (24.3--28.3)      (24.2--27.9)               (24.7--27.8)     (23.7--28.1)     

  WC (cm)         93.0\             93.0\            0.568     93.0\            91.0\            0.448
                  (84.0--98.0)      (82.5--97)                 (86.0--98.0)     (79.0--97.5)     

  TG (mmol/L)     1.48 ± 0.71       1.44 ± 0.78      0.577     1.63 ± 0.70      1.34 ± 0.67      0.058

  TC (mmol/L)     4.68\             4.68\            0.665     5.03\            4.74\            0.185
                  (4.11--5.45)      (4.10--5.25)               (4.46--5.68)     (4.10--5.57)     

  cLDL (mmol/L)   3.09\             3.00\            0.918     3.31\            3.09\            0.308
                  (2.61--3.71)      (2.54--3.66)               (2.92--3.84)     (2.82--3.84)     

  cHDL (mmol/L)   1.13\             1.13\            0.425     1.03\            1.05\            0.596
                  (0.88--1.28)      (0.91--1.34)               (0.88--1.24)     (0.87--1.41)     

  FPG (mmol/L)    6.08 ± 1.75       5.42 ± 1.49      \<0.001   6.36 ± 1.84      5.58 ± 1.91      0.057

  FPI (mIU/L)     9.74\             7.92\            \<0.001   10.47\           7.52\            0.049
                  (7.12--12.88)     (6.18--11.09)              (7.30--12.89)    (6.01--11.49)    

  HOMA-*β*%       88\               96\              0.002     81\              91\              0.056
                  (66--101)         (82--106)                  (55--99)         (82--103)        

  HOMA-S%         79\               102\             \<0.001   73\              103\             0.030
                  (55--110)         (68--126)                  (53--104)        (67--131)        

  HOMA-IR         1.3 (0.9--1.8)    1.0 (0.8--1.5)   \<0.001   1.4 (1.0--1.9)   1.0 (0.8--1.5)   0.038

  Cr (*μ*mol/L)   100.0 ± 45.4      89.3 ± 19.7      0.012     109.6± 47.1      107.0 ± 39.0     0.377

  Urea (mmol/L)   6.15 ± 4.05       5.05 ± 2.19      0.005     7.54 ± 5.08      5.70 ± 2.90      0.073

  UA (*μ*mol/L)   302\              294\             0.143     319\             279\             0.083
                  (247--387)        (241--353)                 (248--383)       (211--347)       

  GFR (mL/min)    93.5\             101.9\           0.054     66.4\            60.2\            0.002
                  (83.3--109.4)     (85.2--112.9)              (48.9--77.6)     (52.7--71.6)     
  ------------------------------------------------------------------------------------------------------

P: Pro; A: Ala; L: Leu; X/A: Pro/Ala and Ala/Ala.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Comparison of anthropometric, HOMA index, and biochemical characteristics of subjects between different groups of Leu162Val PPAR*α* genotypes in two subdivided groups according to age.

  ----------------------------------------------------------------------------------------------------
  Parameters      Age \< 60 years   Age ≥ 60 years                                             
  --------------- ----------------- ---------------- ------- ---------------- ---------------- -------
  Age (years)     36 (28--45)       36 (28--43)      0.622   62 (60--67)      62 (60--69)      0.957

  SBP (mmHg)      125\              130\             0.389   130\             125\             0.178
                  (120--140)        (120--135)               (120--140)       (120--135)       

  DBP (mmHg)      80 (80--85)       80 (80--85)      0.859   80 (80--85)      80 (75--80)      0.159

  BMI (kg/m^2^)   25.7\             26.6\            0.147   26.9\            26.8\            0.965
                  (24.3--28.3)      (24.3--29.4)             (24.5--27.7)     (24.5--28.6)     

  WC (cm)         93.0\             94.0\            0.060   93.0\            92.0\            0.934
                  (82.0--97.0)      (87.5--98.5)             (85.5--97.5)     (81.5--98.5)     

  TG (mmol/L)     1.47 ± 0.73       1.47 ± 0.73      0.985   1.59 ± 0.69      1.24 ± 0.72      0.095

  TC (mmol/L)     4.73\             4.72\            0.870   4.89\            4.63\            0.127
                  (4.19--5.49)      (4.14--5.42)             (4.48--5.68)     (3.95--5.27)     

  cLDL (mmol/L)   3.09\             3.17\            0.847   3.31\            3.06\            0.261
                  (2.61--3.71)      (2.57--3.64)             (2.91--3.84)     (2.39--3.79)     

  cHDL (mmol/L)   1.13\             1.14\            0.305   1.03\            1.07\            0.663
                  (0.88--1.29)      (0.92--1.34)             (0.88--1.27)     (0.76--1.33)     

  FPG (mmol/L)    5.96 ± 1.75       5.46 ± 1.33      0.026   6.34 ± 1.90      4.73 ± 0.84      0.005

  FPI (mIU/L)     9.83\             9.05\            0.510   9.68\            7.38\            0.039
                  (7.12--12.88)     (6.78--12.28)            (7.12--12.89)    (5.54--11.04)    

  HOMA-*β*%       86\               94\              0.017   83\              110\             0.003
                  (64--100)         (77--111)                (56--99)         (84--131)        

  HOMA-S%         77\               84\              0.262   79\              106\             0.025
                  (54--109)         (61--118)                (53--111)        (72--142)        

  HOMA-IR         1.2 (0.9--1.8)    1.2 (0.9--1.7)   0.322   1.3 (0.9--1.9)   1.0 (0.8--1.4)   0.037

  Cr (*μ*mol/L)   97.1 ± 40.7       95.3 ± 34.5      0.731   108.4 ± 44.0     113.3 ± 54.1     0.722

  Urea (mmol/L)   5.99 ± 3.87       4.94 ± 1.82      0.028   7.36 ± 4.83      4.65 ± 1.94      0.058

  UA (*μ*mol/L)   307\              292\             0.090   319\             265\             0.247
                  (248--385)        (233--341)               (237--377)       (217--352)       

  GFR (mL/min)    89.5\             105.5\           0.004   64.2\            68.2\            0.475
                  (72.7--105.1)     (91.8--117.2)            (47.1--75.1)     (56.9--82.1)     
  ----------------------------------------------------------------------------------------------------

L, Leu; V, Val; X/V: Leu/Val and Val/Val.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.

###### 

Anthropometric and biochemical characteristics of subjects within different groups according to the simultaneous existence of different genotypes of the Leu162Val PPAR*α* and Pro12Ala PPAR*γ*2 polymorphisms.

  -------------------------------------------------------------------------------------------------------
                  L/L P/P (*n* = 329)   L/L X/A (*n* = 112)   P/P X/V\         X/A X/V\         *P*
                                                              (*n* = 40)       (*n* = 41)       
  --------------- --------------------- --------------------- ---------------- ---------------- ---------
  Age (years)     41 (29--54)           38 (28--49)           38 (29--47)      37 (28--49)      0.298

  SBP (mmHg)      125\                  125\                  125\             130\             0.284
                  (120--140)            (120--140)            (120--140)       (120--135)       

  DBP (mmHg)      80\                   80\                   80\              80\              0.216
                  (80--85)              (80--85)              (80--90)         (75--80)         

  BMI (kg/m^2^)   26.4\                 24.9\                 26.0\            27.1\            0.053
                  (24.4--28.2)          (23.9--27.3)          (24.5--29.1      (24.2--29.1)     

  WC (cm)         93\                   93\                   93\              95\              0.052
                  (85--98)              (79--96)              (85--98)         (88--98)         

  TG (mmol/L)     1.53 ± 0.71           1.40 ± 0.75           1.38 ± 0.66      1.49 ± 0.79      0.289

  TC (mmol/L)     4.73\                 4.71\                 4.73\            4.71\            0.645
                  (4.19--5.49)          (4.12--5.25)          (4.13--5.43)     (4.03--5.35)     

  cLDL (mmol/L)   3.13\                 3.00\                 3.06\            3.20\            0.578
                  (2.61--3.74)          (2.62--3.65)          (2.53--3.43)     (2.53--3.72)     

  cHDL (mmol/L)   1.09\                 1.13\                 1.17\            1.05\            0.028
                  (0.88--1.26)          (0.92--1.39)          (1.03--1.38)     (0.84--1.32)     

  FPG (mmol/L)    6.22 ± 1.80           5.55 ± 1.67           5.54 ± 1.32      5.18 ± 1.27      \<0.001

  FPI (mIU/L)     10.36\                7.49\                 8.92\            8.91\            \<0.001
                  (7.12--12.89)         (6.02--10.93)         (6.95--12.44)    (6.16--11.26)    

  HOMA-*β*%       84\                   94\                   89\              99\              \<0.001
                  (59--99)              (80--101)             (74--115)        (88--120)        

  HOMA-S%         73\                   82\                   85\              87\              \<0.001
                  (54--108)             (58--117)             (59--115)        (67--128)        

  HOMA-IR         1.4\                  1.2\                  1.2\             1.1\             \<0.001
                  (0.9--1.8)            (0.8--1.7)            (0.9--1.7)       (0.8--1.5)       

  Cr (*μ*mol/L)   102.7 ± 46.2          90.4 ± 21.2           97.5 ± 42.9      98.4 ± 33.5      0.056

  Urea (mmol/L)   6.61 ± 4.51           5.36 ± 4.54           5.15 ± 2.04      4.65 ± 1.59      \<0.001

  UA (*μ*mol/L)   313.0\                301.5\                304.0\           266.0\           0.017
                  (248.0--399.0)        (237.5--360.2)        (236.5--346.0)   (225.0--331.0)   

  GFR (mL/min)    87.9\                 91.5\                 101.5\           102.6\           0.011
                  (71.7--104.5)         (71.5--109.4)         (84.0--112.8)    (72.6--118.2)    
  -------------------------------------------------------------------------------------------------------

P: Pro; A: Ala; L: Leu; V: Val; X/A: Pro/Ala and Ala/Ala; X/V: Leu/Val and Val/Val.

SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; WC: waist circumference; TG: triglycerides; TC: total cholesterol; cHDL: high density lipoprotein cholesterol; cLDL: low density lipoprotein cholesterol; FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-*β*%: %  *β*-cell function; HOMA-S%: % cell insulin sensitivity; HOMA-IR: insulin resistance; Cr: creatinine; UA: uric acid; GFR: glomerular filtration rate.
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